Market Closed -
Deutsche Boerse AG
11:32:46 28/06/2024 am IST
|
5-day change
|
1st Jan Change
|
3.76
EUR
|
+0.53%
|
|
+2.17%
|
+6.82%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,028
|
695.7
|
629.6
|
583.6
|
540.7
|
574.3
|
-
|
-
|
Enterprise Value (EV)
1 |
1,028
|
695.7
|
629.6
|
583.6
|
540.7
|
574.3
|
574.3
|
574.3
|
P/E ratio
|
75.8
x
|
16.8
x
|
40.8
x
|
-19.9
x
|
-32.4
x
|
198
x
|
55.6
x
|
46
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
21.7
x
|
3.49
x
|
2.59
x
|
1.99
x
|
1.65
x
|
1.66
x
|
1.61
x
|
1.51
x
|
EV / Revenue
|
21.7
x
|
3.49
x
|
2.59
x
|
1.99
x
|
1.65
x
|
1.66
x
|
1.61
x
|
1.51
x
|
EV / EBITDA
|
-111
x
|
41.3
x
|
16.6
x
|
10.8
x
|
9
x
|
9.86
x
|
9.06
x
|
7.66
x
|
EV / FCF
|
229
x
|
-39.6
x
|
15.4
x
|
15.5
x
|
-
|
19.9
x
|
18.6
x
|
14.8
x
|
FCF Yield
|
0.44%
|
-2.53%
|
6.48%
|
6.44%
|
-
|
5.03%
|
5.36%
|
6.76%
|
Price to Book
|
1.27
x
|
0.79
x
|
0.74
x
|
0.7
x
|
-
|
0.78
x
|
0.76
x
|
0.78
x
|
Nbr of stocks (in thousands)
|
1,35,629
|
1,30,035
|
1,18,786
|
1,12,672
|
1,04,187
|
1,01,283
|
-
|
-
|
Reference price
2 |
7.580
|
5.350
|
5.300
|
5.180
|
5.190
|
5.670
|
5.670
|
5.670
|
Announcement Date
|
30/03/20
|
25/03/21
|
24/03/22
|
23/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
47.46
|
199.5
|
243.5
|
293.6
|
328.2
|
345.9
|
356.3
|
381.4
|
EBITDA
1 |
-9.244
|
16.84
|
38
|
54.03
|
60.08
|
58.22
|
63.38
|
74.95
|
EBIT
1 |
-
|
-4.465
|
28.34
|
34.68
|
51.41
|
54.18
|
-
|
-
|
Operating Margin
|
-
|
-2.24%
|
11.64%
|
11.81%
|
15.66%
|
15.66%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
22.78
|
32.08
|
6.69
|
-43.96
|
-21.99
|
-3.517
|
11.5
|
26.44
|
Net income
1 |
14.52
|
42.07
|
15.68
|
-29.89
|
-16.84
|
2.488
|
13.69
|
13.8
|
Net margin
|
30.59%
|
21.08%
|
6.44%
|
-10.18%
|
-5.13%
|
0.72%
|
3.84%
|
3.62%
|
EPS
2 |
0.1000
|
0.3190
|
0.1300
|
-0.2600
|
-0.1600
|
0.0286
|
0.1020
|
0.1233
|
Free Cash Flow
1 |
4.487
|
-17.58
|
40.79
|
37.6
|
-
|
28.9
|
30.8
|
38.8
|
FCF margin
|
9.45%
|
-8.81%
|
16.75%
|
12.81%
|
-
|
8.36%
|
8.64%
|
10.17%
|
FCF Conversion (EBITDA)
|
-
|
-
|
107.32%
|
69.58%
|
-
|
49.64%
|
48.6%
|
51.77%
|
FCF Conversion (Net income)
|
30.91%
|
-
|
260.2%
|
-
|
-
|
1,161.34%
|
225.05%
|
281.16%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/20
|
25/03/21
|
24/03/22
|
23/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
58.27
|
63.81
|
75.82
|
72.28
|
81.66
|
82.6
|
89.9
|
81.5
|
74.2
|
86.6
|
87.67
|
86.72
|
84.94
|
87.3
|
90.5
|
EBITDA
1 |
5.696
|
13.31
|
17.89
|
9.009
|
13.82
|
18.24
|
14.27
|
15.51
|
12.06
|
13.59
|
14.69
|
15.12
|
14.31
|
15.05
|
15.6
|
EBIT
1 |
2.406
|
10.97
|
13.39
|
2.309
|
8.01
|
16.8
|
11.16
|
12.41
|
11.03
|
13.53
|
10.76
|
14.7
|
15.19
|
-
|
-
|
Operating Margin
|
4.13%
|
17.2%
|
17.66%
|
3.19%
|
9.81%
|
20.34%
|
12.42%
|
15.23%
|
14.87%
|
15.63%
|
12.28%
|
16.95%
|
17.88%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-14.42
|
-22.31
|
0.636
|
0.851
|
-23.14
|
-4.946
|
0.212
|
8.898
|
-26.15
|
-7.144
|
0.6508
|
1.346
|
1.834
|
1
|
1.8
|
Net income
1 |
-8.301
|
-18.81
|
2.516
|
1.591
|
-15.19
|
-3.937
|
1.84
|
9.588
|
-24.33
|
-4.546
|
0.7197
|
1.411
|
1.463
|
0.8
|
1.4
|
Net margin
|
-14.25%
|
-29.48%
|
3.32%
|
2.2%
|
-18.6%
|
-4.77%
|
2.05%
|
11.76%
|
-32.79%
|
-5.25%
|
0.82%
|
1.63%
|
1.72%
|
0.92%
|
1.55%
|
EPS
2 |
-0.0600
|
-0.1600
|
0.0200
|
0.0100
|
-0.1300
|
-0.0400
|
0.0200
|
0.0900
|
-0.2300
|
-0.0400
|
0.0160
|
0.0240
|
0.0260
|
0.0100
|
0.0100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/03/22
|
12/05/22
|
11/08/22
|
10/11/22
|
23/03/23
|
11/05/23
|
10/08/23
|
09/11/23
|
21/03/24
|
09/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
4.49
|
-17.6
|
40.8
|
37.6
|
-
|
28.9
|
30.8
|
38.8
|
ROE (net income / shareholders' equity)
|
1.58%
|
4.96%
|
-
|
-3.58%
|
-
|
-0.5%
|
2%
|
3.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
5.990
|
6.820
|
7.150
|
7.360
|
-
|
7.290
|
7.500
|
7.250
|
Cash Flow per Share
2 |
0.0300
|
-
|
-
|
0.3500
|
-
|
0.1000
|
0.4600
|
0.4100
|
Capex
1 |
0.11
|
5.38
|
224
|
2.89
|
-
|
7.93
|
10
|
10
|
Capex / Sales
|
0.23%
|
2.7%
|
92.08%
|
0.98%
|
-
|
2.29%
|
2.81%
|
2.62%
|
Announcement Date
|
30/03/20
|
25/03/21
|
24/03/22
|
23/03/23
|
21/03/24
|
-
|
-
|
-
|
Last Close Price
5.67
CAD Average target price
7.243
CAD Spread / Average Target +27.74% Consensus |
1st Jan change
|
Capi.
|
---|
| +7.39% | 7.21TCr | | +15.93% | 904.53Cr | | -22.81% | 440.44Cr | | +17.59% | 439.23Cr | | +25.93% | 393.64Cr | | +4.64% | 210Cr | | +9.09% | 197.11Cr | | -36.86% | 187.45Cr | | -0.50% | 164.41Cr |
Specialty & Advanced Pharmaceuticals
|